Day Zero Diagnostics: Funding, Investors & Team (Sep 2026)
Day Zero is revolutionizing infectious disease diagnostics by using advanced technologies like whole-genome sequencing and their own proprietary methods. They aim to generate clinically actionable data on a large scale and create a new class of sequencing-based in-vitro diagnostics. Their innovative sample preparation techniques allow for highly accurate sequencing of pathogen DNA directly from clinical samples. They also utilize machine learning algorithms to provide diagnostic results that are clinically useful. Additionally, they have built a top-notch database of whole-genome sequencing and drug effectiveness profiles. The goal of Day Zero Diagnostics is to transform how infectious disease diagnostics are carried out by providing real-time sequencing data that can help track, manage, and combat these diseases. Their initial focus is on bloodstream infections and sepsis, where quick antibiotic treatment is critical to a patient's survival. Current diagnostic methods take several days to identify the pathogen and determine its susceptibility to antibiotics, leaving physicians to rely on broad-spectrum antibiotics that may be ineffective and harmful. Day Zero, on the other hand, can provide a complete diagnosis within hours, including both the identification of the pathogen and its antibiotic resistance profile. This allows physicians to administer targeted treatments from the very beginning, resulting in better patient outcomes and cost savings.
Day Zero Diagnostics has raised $24.2M across 2 funding rounds on record, the most recent an undisclosed round of $16.0M announced in Sep 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Day Zero Diagnostics Company Profile and Key Stats
Latest funding round on record: Sep 2023.
Day Zero Diagnostics Funding Rounds
Day Zero Diagnostics raised $8.2M in a Grant announced in Oct 2022.
11 months later, an undisclosed round of $16.0M was announced in Sep 2023.
Day Zero Diagnostics Founders and Leadership Team
Contact details for the Day Zero Diagnostics team: 1 of 1 has an email address on file.
Start 14-day free trial →Day Zero Diagnostics Funding Compared to Other Biotechnology Startups
Day Zero Diagnostics' latest round of $16.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Day Zero Diagnostics in Biotechnology and Boston
Companies Similar to Day Zero Diagnostics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Day Zero Diagnostics Funding FAQs
What does Day Zero Diagnostics do?
Day Zero is revolutionizing infectious disease diagnostics by using advanced technologies like whole-genome sequencing and their own proprietary methods. They aim to generate clinically actionable data on a large scale and create a new class of sequencing-based in-vitro diagnostics. Their innovative sample preparation techniques allow for highly accurate sequencing of pathogen DNA directly from clinical samples. They also utilize machine learning algorithms to provide diagnostic results that are clinically useful. Additionally, they have built a top-notch database of whole-genome sequencing and drug effectiveness profiles. The goal of Day Zero Diagnostics is to transform how infectious disease diagnostics are carried out by providing real-time sequencing data that can help track, manage, and combat these diseases. Their initial focus is on bloodstream infections and sepsis, where quick antibiotic treatment is critical to a patient's survival. Current diagnostic methods take several days to identify the pathogen and determine its susceptibility to antibiotics, leaving physicians to rely on broad-spectrum antibiotics that may be ineffective and harmful. Day Zero, on the other hand, can provide a complete diagnosis within hours, including both the identification of the pathogen and its antibiotic resistance profile. This allows physicians to administer targeted treatments from the very beginning, resulting in better patient outcomes and cost savings.
How much funding has Day Zero Diagnostics raised?
Day Zero Diagnostics has raised $24.2M across 2 rounds on record. The most recent is an undisclosed round of $16.0M announced in Sep 2023.
When did Day Zero Diagnostics last raise funding?
Day Zero Diagnostics' most recent funding round on record is an undisclosed round of $16.0M, announced in Sep 2023.
Who is the CEO of Day Zero Diagnostics?
Jong Lee is listed as CEO at Day Zero Diagnostics.
Where is Day Zero Diagnostics headquartered?
Day Zero Diagnostics is based in Boston, Massachusetts, United States.
How many employees does Day Zero Diagnostics have?
Day Zero Diagnostics is in the 11-50 employee band.
How does Day Zero Diagnostics' funding compare to other Biotechnology startups?
Day Zero Diagnostics' latest round of $16.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Day Zero Diagnostics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Day Zero Diagnostics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.